financetom
Business
financetom
/
Business
/
Equinix shares fall as revenue, capital spending forecast disappoint investors
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Equinix shares fall as revenue, capital spending forecast disappoint investors
Jun 26, 2025 9:33 AM

(Reuters) -Equinix's shares fell 8% on Thursday after the data center firm forecast revenue growth below expectations and projected heavy investments to cater to AI demand in the long term.

The company plans to double its current capacity over the next five years to capitalize on the growing demand for infrastructure to meet the surge in artificial intelligence use.

Shares of peers Iron Mountain, Digital Realty and Core Scientific fell between 2% and 3%.

Equinix is ramping up investments to expand its infrastructure for rising AI inference demand. While this is expected to drive stronger growth in the long run - potentially crossing 10% by 2030 - near-term growth will remain modest, BMO Capital Markets analysts said in a note.

It expects its annual revenue to grow 7% to 10% from 2025 to 2029, slightly lower than its prior forecast.

Meanwhile, it updated its forecast for adjusted funds from operations (AFFO) per share growth to 5% to 9% now from 7% to 10%, which disappointed investors.

To position for growing AI inference demand, Equinix plans to increase annual capital spending to $4 billion to $5 billion from 2026 to 2029, up from $3.3 billion in 2025.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novartis opens new plant in California to make cancer drugs
Novartis opens new plant in California to make cancer drugs
Nov 10, 2025
Nov 10 (Reuters) - Swiss drugmaker Novartis said on Monday it has opened a new 10,000-square-foot factory in Carlsbad, California, to make cancer treatments, as part of its pledge to invest billions into building U.S. sites. The plant will produce radioligand therapies, which are drugs that deliver cell-killing radioactive particles directly to tumors, the company said. Novartis already markets radioligand...
Sibanye Stillwater Settles Deal Termination Dispute With Appian Capital for $215 Million
Sibanye Stillwater Settles Deal Termination Dispute With Appian Capital for $215 Million
Nov 10, 2025
09:28 AM EST, 11/10/2025 (MT Newswires) -- Sibanye Stillwater ( SBSW ) said Monday that it has agreed to a $215 million commercial settlement with investment firm Appian Capital Advisory over Sibanye's cancellation of a deal to acquire shares of Atlantic Nickel and Mineracao Vale Verde from Appian in January 2022. The two parties have reached an agreement on a...
MannKind Discontinues Phase 3 Trial of Nebulized Clofazimine to Treat Lung Disease
MannKind Discontinues Phase 3 Trial of Nebulized Clofazimine to Treat Lung Disease
Nov 10, 2025
09:28 AM EST, 11/10/2025 (MT Newswires) -- MannKind ( MNKD ) said Monday it has discontinued its phase 3 trial evaluating MNKD-101, a nebulized clofazimine inhalation suspension, for the treatment of nontuberculous mycobacterial lung disease. The company said no sputum culture conversions were observed from the first 46 participants who completed the double-blind treatment phase and the Data Safety Monitoring...
ADENTRA Q3 Net Income Lowers Despite Rise in Sales; Increases Annual Dividend to C$0.64
ADENTRA Q3 Net Income Lowers Despite Rise in Sales; Increases Annual Dividend to C$0.64
Nov 10, 2025
09:29 AM EST, 11/10/2025 (MT Newswires) -- ADENTRA ( HDIUF ) , one of North America's largest distributors of architectural building products, on Monday reported a fall in net income but still beat forecast for the third quarter on better than expected revenues, while it increased its annual dividend For the three-months ended Sept. 30, the company reported net income...
Copyright 2023-2026 - www.financetom.com All Rights Reserved